logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q4 2020
Cytokinetics Inc.
Topline data from phase III study of Omecamtiv mecarbil (GALACTIC-HF)
Heart failure
Q4 2020
Can-Fite BioPharma Ltd.
Interim analysis from phase III study of Piclidenoson
Rheumatoid Arthritis
Q4 2020
Syndax Pharma
Results from phase I/II trial of SNDX-6352
Chronic Graft Versus Host Disease
Q4 2020
Syndax Pharma
Additional findings from phase I/II clinical trial of SNDX-5613 ( AUGMENT-101)
Relapsed/refractory acute leukemias
Q4 2020
Immunovant, Inc
Initial results from phase IIa clinical trial of IMVT-1401 ( ASCEND WAHA)
Warm autoimmune hemolytic anemia
Q4 2020
BioXcel Therapeutics, Inc.
Data from phase Ib/II study of BXCL501 (TRANQUILITY)
Acute treatment of agitation in patients with dementia
Q4 2020
BioXcel Therapeutics, Inc.
Initial data readout from phase Ib/II trial of BXCL701 in combination with KEYTRUDA
Neuroendocrine prostate cancer
Q4 2020
BioXcel Therapeutics, Inc.
Topline results from phase Ib/II study of BXCL501
Acute treatment of agitation in patients with dementia
Q4 2020
Supernus Pharmaceuticals, Inc.
Submission of NDA for SPN-830
Continuous treatment of motor fluctuations (“on-off” episodes) in Parkinson's disease
Q4 2020
Crinetics Pharmaceuticals Inc
Topline data from Phase 2 clinical trial for paltusotine (ACROBAT Edge)
Acromegaly
Q4 2020
Crinetics Pharmaceuticals Inc
Topline data from Phase 2 clinical trial for paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist (ACROBAT Evolve)
Acromegaly
Q4 2020
Applied Genetic Technologies Corp.
Full interim data from Groups 5 and 6 of the phase I/II trial of gene therapy product candidate
X-Linked Retinitis Pigmentosa
Q4 2020
Rocket Pharmaceuticals, Inc.
Preliminary safety and efficacy data from phase I clinical trial of RP-A501
Danon Disease
Q4 2020
Tonix Pharmaceuticals Holding Corp.
Topline data from phase III trial of TNX-102 SL (RELIEF)
Fibromyalgia
Q4 2020
Bellicum Pharmaceuticals, Inc
Initial Phase 1 cohort 5C data of BPX-601 clinical trial to evaluate safety of repeat rimiducid
Second-line metastatic pancreatic cancer
Q4 2020
Blueprint Medicines
Submission of sNDA for avapritinib
Advanced systemic mastocytosis (SM)
Late Q4 2020
Calithera Biosciences Inc.
Top-line efficacy and safety data from randomized trial of telaglenastat and cabozantinib (CANTATA)
Advanced renal cell carcinoma (RCC)
Q4 2020
Calliditas Therapeutics AB (publ)
Topline readout of Part A of pivotal Phase 3 study of Nefecon vs placebo for 200 patients(NefIgArd)
Primary IgA Nephropathy
Q4 2020
Prothena Corporation plc
New data from phase I study of PRX004
ATTR amyloidosis
Q4 2020
Pluristem Therapeutics, Inc.
Top-line interim data analysis from phase 3 trial of PLX PAD
Critical Limb Ischemia
Q4 2020
Plus Therapeutics Inc.
Preliminary data from phase I study of RNL (RESPECT)
Recurrent glioblastoma
Q4 2020
Can-Fite BioPharma Ltd.
Interim analysis from phase III study of Piclidenoson
psoriasis
Q4 2020
Cara Therapeutics Inc.
Submission of NDA for KORSUVA Injection
Hemodialysis patients with moderate-to-severe chronic Kidney Disease-Associated Pruritus (CKD-aP)
Q4 2020
Deciphera Pharmaceuticals, Inc.
Updated data from Phase 1 dose-escalation study of DCC-3014
Tenosynovial giant cell tumor (TGCT)
Q4 2020
Precision BioSciences Inc
Updated interim data from PBCAR0191 targeting CD19
Relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL)